Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xenon ( (XENE) ) has shared an update.
Xenon Pharmaceuticals Inc. advised Canadian securities regulators on March 13, 2026 that it has set June 2, 2026 as the date for its 2026 annual meeting of shareholders. The company established April 7, 2026 as the record date for notice, voting and beneficial ownership determination, with common shares entitled to receive materials and vote, and will use notice-and-access for both registered and non-registered investors while agreeing to pay distribution costs for objecting beneficial owners.
These arrangements clarify how Xenon’s shareholder base will participate in the upcoming meeting and how proxy materials will be delivered, underscoring the firm’s adherence to Canadian disclosure and governance requirements. The decision not to mail directly to non-objecting beneficial owners, but to bear costs for objecting beneficial owners and rely on electronic notice-and-access, reflects a balance between cost efficiency and ensuring broad investor access to meeting information.
The most recent analyst rating on (XENE) stock is a Hold with a $62.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
The score is primarily constrained by weak financial performance (large losses and heavy cash burn), but supported by a strong balance sheet and extended cash runway reinforced by recent financing. Technicals are favorable with a strong uptrend, though overbought signals temper the near-term setup. Earnings call commentary and milestones provide a constructive outlook, while valuation remains challenged due to ongoing unprofitability and no dividend support.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a biopharmaceutical company, as indicated by its name and regulatory filings, that is publicly listed and subject to Canadian securities oversight. The company’s shareholder base holds common shares that carry both notice and voting rights for corporate governance matters, reflecting a standard publicly traded equity structure.
Average Trading Volume: 1,256,301
Technical Sentiment Signal: Buy
Current Market Cap: $4.82B
For an in-depth examination of XENE stock, go to TipRanks’ Overview page.